Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pasithea Therapeutics Corp (KTTA)

Pasithea Therapeutics Corp (KTTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial GlobeNewswire - Tue Jun 16, 6:00AM CDT

-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference GlobeNewswire - Mon Jun 15, 6:02AM CDT

-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire - Tue Jun 2, 6:02AM CDT

MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer GlobeNewswire - Mon May 4, 6:01AM CDT

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) GlobeNewswire - Mon Apr 20, 6:01AM CDT

MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity GlobeNewswire - Wed Apr 1, 6:01AM CDT

MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Tue Feb 17, 6:01AM CST

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET – – Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines GlobeNewswire - Tue Jan 13, 6:01AM CST

MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock GlobeNewswire - Tue Dec 2, 2025

Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments,...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock GlobeNewswire - Fri Nov 28, 2025

Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)

Barchart Exclusives

This Lesser-Known Dividend Stock Is Beating the S&P 500 in 2026 and Yields More Than 3% Barchart - Mon Jun 29, 6:30PM CDT
Watsco has raised its quarterly dividend by 10% to $3.30 per share, lifting the annualized payout to $13.20 and delivering a forward yield above 3%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.